Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants
Author:
Smith Robert A12ORCID, Raugi Dana N12, Nixon Robert S12, Seydi Moussa3, Margot Nicolas A4, Callebaut Christian4, Gottlieb Geoffrey S125ORCID, Sall Fatima, Diallo Khardiata, Diallo Mouhamadou Baïla, Faye Khadim, Cisse Samba, Simal Fatou, Sy Marie Pierre, Diaw Binetou, Ndiaye Ousseynou, Faye Babacar, Diop Ndeye Astou, Diop Amadou Bale, Fadiome Marianne, Sall ElHadji Ibrahima, Kande Boubacar, Malomar Jean Jacques, Cisse Ousseynou, Tamba Ibrahima Tito, Faye Dominique, Diallo Papa Amadou, Diop Mamadou Habib, Diatta Jean Phillippe, Diene Adji Fatoumata, Badiane François, Diatta Baboucar, Bakhoum Raphael, Barry Aissatou, Sané Aissatou Mamy, Sambou Jacques Francois, Diedhiou Bokeni, Diatta Sidy, Gomis Juliette, Dieye Terese, Hawes Stephen, Benzekri Noelle, Lin John, Chang Ming, Coombs Robert, Mullins James, Sow Papa Salif, Kiviat Nancy,
Affiliation:
1. Center for Emerging and Re-emerging Infectious Diseases, University of Washington , Seattle 2. Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington , Seattle 3. Service des Maladies Infectieuses et Tropicales, Centre Hospitalier National Universitaire de Fann , Dakar , Senegal 4. Clinical Virology, Gilead Sciences Inc , Foster City, California 5. Department of Global Health, University of Washington , Seattle
Abstract
Abstract
The activity of lenacapavir against human immunodeficiency virus type 1 (HIV-1) has been extensively evaluated in vitro, but comparable data for human immunodeficiency virus type 2 (HIV-2) are scarce. We determined the anti–HIV-2 activity of lenacapavir using single-cycle infections of MAGIC-5A cells and multicycle infections of a T-cell line. Lenacapavir exhibited low-nanomolar activity against HIV-2, but was 11- to 14-fold less potent against HIV-2 in comparison to HIV-1. Mutations in HIV-2 that confer resistance to other antiretrovirals did not confer cross-resistance to lenacapavir. Although lenacapavir-containing regimens might be considered for appropriate patients with HIV-2, more frequent viral load and/or CD4 testing may be needed to assess clinical response.
Funder
National Institute of Allergy and Infectious Diseases University of Washington Center for AIDS Research NIH Stanford HIV Drug Resistance Database Program
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Immunology and Allergy
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|